Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease |
| |
Authors: | Mudd James O Borlaug Barry A Johnston Peter V Kral Brian G Rouf Rosanne Blumenthal Roger S Kwiterovich Peter O |
| |
Affiliation: | Johns Hopkins Ciccarone Preventive Cardiology Center, Baltimore Maryland, USA. |
| |
Abstract: | Recent clinical trials in patients with coronary artery disease (CAD) provide evidence that low-density lipoprotein cholesterol (LDL-C) levels should be lowered even further to prevent recurrent CAD. However, despite more aggressive interventions for lowering LDL-C levels, the majority of CAD events go undeterred, perhaps related to the fact that intervention was not started earlier in life or that LDL-C levels represent an incomplete picture of atherogenic potential. Nevertheless, LDL-C remains the contemporary standard as the primary goal for aggressive LDL reduction. If triglycerides are >200 mg/dl, the measurement of non-high-density lipoprotein cholesterol (HDL-C) is recommended. Measurement of apolipoprotein (apo)B has been shown in nearly all studies to outperform LDL-C and non-HDL-C as a predictor of CAD events and as an index of residual CAD risk. This is because apoB reflects the total number of atherogenic apoB-containing lipoproteins and is a superior predictor of the number of low-density lipoprotein particles (LDL-P). Estimates of LDL-P and size can also be made by nuclear magnetic resonance spectroscopy, density gradient ultracentrifugation, and gradient gel electrophoresis. Although a number of studies show that such estimates predict CAD, LDL-P, and size often accompany low HDL-C and high triglyceride levels, and therefore such additional lipoprotein testing has not been recommended for routine screening and follow-up. Because apoB is a superior predictor of LDL-P, we recommend that apoB and the apoB/apoA-I ratio be determined after measurement of LDL-C, non-HDL-C, and the ratio of total cholesterol/HDL-C to better predict CAD and assess efficacy of treatment. |
| |
Keywords: | apo, apolipoprotein CAD, coronary artery disease CE, cholesteryl esters DGU, density-gradient ultracentrifugation GGE, gradient gel electrophoresis HDL-C, high-density lipoprotein cholesterol LDL-C, low-density lipoprotein cholesterol LDL-P, total number of low-density lipoprotein particles Lp(a), lipoprotein (a) NMR, nuclear magnetic resonance TC, total cholesterol TG, triglycerides |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|